![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, June 08, 2007 8:18:01 PM
With the first-ever Pre-Market Approval (PMA) submission to include head-to-head clinical trial results demonstrating superiority of one drug-eluting stent over another, Abbott completed its application to the U.S. Food and Drug Administration seeking U.S. market approval for its XIENCE V Everolimus Eluting Coronary Stent System to treat coronary artery disease.
Abbott’s PMA submission includes safety and efficacy data from the XIENCE V SPIRIT family of clinical trials, which demonstrated superior results for XIENCE V over Boston Scientific’s TAXUS® drug-eluting coronary stent system in the primary endpoint of reducing vessel re-narrowing.
XIENCE V was launched in Europe and Asia Pacific in 2006 and is currently an investigational device in the United States and Japan. Abbott expects to launch XIENCE V in the United States in the first half of 2008
Recent ABT News
- AVEIR(MC) DR d'Abbott - Le premier système de stimulateur cardiaque double chambre sans sonde est maintenant offert au Canada • PR Newswire (Canada) • 08/15/2024 06:18:00 PM
- Abbott's AVEIR™ DR - World's First Dual Chamber Leadless Pacemaker System - Now Available in Canada • PR Newswire (Canada) • 08/15/2024 05:44:00 PM
- Quebec Expands Public Reimbursement of Abbott's FreeStyle Libre® 2 Flash Glucose Monitoring System to More Adults with Diabetes • PR Newswire (Canada) • 08/08/2024 01:00:00 PM
- Québec élargit sa couverture publique du système flash de surveillance du glucose FreeStyle Libre 2 à un plus grand nombre d'adultes atteints de diabète • PR Newswire (Canada) • 08/08/2024 01:00:00 PM
- Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices • PR Newswire (US) • 08/07/2024 12:00:00 PM
- Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices • PR Newswire (US) • 08/07/2024 12:00:00 PM
- Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs • PR Newswire (US) • 08/06/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 08:02:17 PM
- Apple Delays AI Features, Abbott Shares Plunge 7% After $495M Fine, Philips Soars 10% • IH Market News • 07/29/2024 10:24:10 AM
- Microsoft Shares Drop 2% and CrowdStrike Plunges 21% Pre-Market Following Major Global Outage • IH Market News • 07/19/2024 10:01:22 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 11:37:35 AM
- Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance • PR Newswire (US) • 07/18/2024 11:30:00 AM
- Nasdaq Tech Stocks Show Partial Recovery; Oil Prices Rise • IH Market News • 07/18/2024 10:01:11 AM
- BP Slashes Profit Forecast by $700 Million; Morgan Stanley Predicts S&P 500 10% Drop, and More News • IH Market News • 07/09/2024 10:54:32 AM
- Abbott Hosts Conference Call for Second-Quarter Earnings • PR Newswire (US) • 06/27/2024 12:00:00 PM
- Abbott Teams Up With the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health • PR Newswire (US) • 06/20/2024 12:05:00 PM
- Abbott Declares 402nd Consecutive Quarterly Dividend • PR Newswire (US) • 06/14/2024 04:01:00 PM
- Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems • PR Newswire (US) • 06/10/2024 12:00:00 PM
- Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients • PR Newswire (US) • 06/03/2024 01:00:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/30/2024 08:07:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 09:35:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/10/2024 08:52:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 09:00:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2024 10:59:42 PM
- Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee • PR Newswire (US) • 04/29/2024 01:00:00 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM